# Brucellosis Market

> Brucellosis Market research report– by species (Brucella suis, B. abortus, B. melitensis), Diagnosis (serological tests, molecular techniques, bone marrow biopsy, CT, MRI), Treatment (vaccine, antibiotics), End user– Forecast till 2035.

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.93%
- **2024:** $ 657.55 Million
- **2025:** $ 710.65 Million
- **2035:** $ 1,380.04 Million
- **Key Players:** Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Ceva Santé Animale (FR), Vetoquinol (FR), Heska Corporation (US), Elanco Animal Health (US), Virbac (FR)

**Report ID:** MRFR/LS/3722-HCR · **Pages:** 90 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/brucellosis-market-5159

---

## Market Summary

## **Global Brucellosis Market Overview**

The Brucellosis Market is expected to reach USD 0.63 Billion by 2032 at 8.9% CAGR during the forecast period 2023-2032.Brucellosis is a bacterial infection that spreads from animals to people most often via unpasteurized milk, cheese and other dairy products. More rarely, the bacteria that cause brucellosis can spread through the air or through direct contact with infected animals. The infection can usually be treated successfully with antibiotics. Avoiding unpasteurized dairy products and taking precautions while working with animals or in pathogy laboratories may prevent brucellosis.

The global burden of human brucellosis remains enormous as the organism causes more than 500,000 infections per year worldwide. Usually, brucellosis is more common in males than in females and are generally non occuring in infants.

Brucella are small aerobic intracellular organisms which localize in the reproductive organs of host animals, causing abortions and sterility. They usually spread through fliuds such as animal’s urine, milk, placental fluid, and others. To this day, 8 species have been identified, named primarily for the source animal or features of infection. Out of these, four species are significantly pathogenous to humans, these include _Brucella melitensis_ (sheep, goats), _Brucella suis_ (swine), _Brucella abortus_ (buffalos, bison), _Brucella canis_ (dogs)

In the U.S., the Nationwide eradication of brucellosis from domestic cattle and bison are carried out by governing bodies such as USDA, APHIS, Cooperative State Federal Program. Currently all 50 states as well as Puerto Rico and the U.S. Virgin Islands are brucellosis free. Any livestock market that has been approved by the State is handled under the supervision of the Cooperative State–Federal Brucellosis Eradication Program.

A Brucella abortus product that is approved by the Brucellosis Eradication Program and licensed under USDA for injection into cattle to enhance their resistance to brucellosis. The brucellosis vaccine is called RB51. Pasteurization has been proven to destroy the causative agent of Brucellosis. 

**Intended Audience:**

## **Brucellosis Market Segment Insights**

The brucellosis market is segmented on the basis of species, diagnosis,  treatment and end-users.

### **Brucellosis Species Insights**

On the basis of species, the brucellosis market is segmented into _Brucella suis, Brucella abortus, Brucella melitensis, Brucella canis_ and others 

### **Brucellosis Diagnosis Insights**

On the basis of diagnosis, brucellosis market is segmented into serological tests, molecular techniques, bone marrow biopsy, X-rays, computerized tomography (CT), [magnetic resonance imaging](../../../reports/magnetic-resonance-imaging-systems-market-6194) (MRI), cerebrospinal fluid culture, echocardiography and others. The serological tests is segmented into serum agglutination test, rose bengal test, lateral flow assay, compliment fixation test, coombs test, enzyme linked immuno sorbent assaym, and immunocapture-agglutination test (brucellacapt). The molecular techniques is segmented into Polymerase Chain Reaction (PCR), Loop- mediated isothermal amplification assay, Multiple Locus VNTR Analysis (MLVA) typing. The Polymerase Chain Reaction (PCR) is further classified into standard PCR, real time PCR, nested PCR, PCR based assays

### **Brucellosis Treatment Insights**

On the basis of treatment, brucellosis market is segmented into [antibiotics](../../../reports/antibiotics-market-8447), vaccines, and others

### **Brucellosis End-User Insights**

On the basis of end-user, the brucellosis market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.

### **Brucellosis Regional Insights**

The brucellosis market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.

The European brucellosis market is the largest market owing to the high investment in various private and government funded research and development programs in the region and increased spending on pharmaceutical and biotechnology industry development.

America is projected to hold the second largest share of the brucellosis market as due to the eradication of these disease from the USA. Currently, fewer than 100 cases are reported annually to the Centers for Disease Control and Prevention (CDC) with approximately 60% of human brucellosis cases in the United States now occur in California and Texas.  Brucellosis has become rare in North America due to numerous veterinary control measures such as routine screening and vaccination of domestic livestock. Most cases of brucella infection in the U.S. is due to the consumption of imported unpasteurized dairy products from Mexico.

The Asia Pacific and the Middle Eastern region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector. The heaviest disease burden lies in countries of the Mediterranean basin and Arabian Peninsula, and the disease is also common in India, Mexico, and South & Central America. In Africa, incidence rates of 1.2-70 cases per 100,000 people have been reported.

In Africa, such endemic diseases are controlled through animal slaughter due to the fragile nature of the food supply.

**Key Players**

## Market Drivers

### Rising Incidence of Brucellosis

The increasing incidence of brucellosis globally is a primary driver for the Global Brucellosis Market Industry. In 2024, the estimated market size is 0.09 USD Billion, reflecting heightened awareness and reporting of the disease. Brucellosis Market, primarily affecting livestock, poses significant health risks to humans, particularly in regions with high animal husbandry practices. Countries with endemic brucellosis face economic burdens due to livestock losses and healthcare costs. This situation necessitates improved diagnostic and therapeutic solutions, thereby propelling market growth. As awareness spreads, the demand for effective vaccines and treatments is likely to increase, further stimulating the Global Brucellosis Market Industry.

### Government Initiatives and Funding

Government initiatives aimed at controlling and eradicating brucellosis are pivotal for the Global Brucellosis Market Industry. Various countries are implementing vaccination programs and surveillance systems to monitor and reduce the disease's prevalence. Increased funding for research and development of vaccines and treatments is expected to enhance market growth. For instance, public health campaigns focusing on education and prevention strategies are likely to raise awareness among farmers and the general population. This proactive approach not only aims to reduce infection rates but also encourages investment in the development of innovative solutions, thereby fostering a more robust Global Brucellosis Market Industry.

### Growing Awareness of Zoonotic Diseases

The rising awareness of zoonotic diseases, including brucellosis, is driving the Global Brucellosis Market Industry. Public health organizations are emphasizing the importance of understanding how diseases can transfer from animals to humans. This awareness is particularly relevant in regions where livestock farming is prevalent. As consumers become more informed about the risks associated with zoonotic infections, there is a growing demand for preventive measures, including vaccination and improved food safety practices. This trend is likely to lead to increased investments in research and development, ultimately contributing to the expansion of the Global Brucellosis Market Industry as stakeholders seek to mitigate risks associated with brucellosis.

### Advancements in Diagnostic Technologies

Technological advancements in diagnostic methods are significantly influencing the Global Brucellosis Market Industry. Enhanced diagnostic tools, such as serological tests and molecular techniques, allow for quicker and more accurate detection of brucellosis. This is crucial for managing outbreaks and implementing control measures effectively. As these technologies become more accessible, healthcare providers are likely to adopt them, leading to an increase in reported cases and subsequent demand for treatment options. The integration of these advanced diagnostics into routine veterinary practices may also contribute to the market's growth, as early detection can mitigate the economic impact of the disease on livestock and public health.

### Projected Market Growth and Economic Potential

The Global Brucellosis Market Industry is projected to experience substantial growth, with estimates indicating a market size of 0.81 USD Billion by 2035. This growth trajectory, characterized by a compound annual growth rate (CAGR) of 22.62% from 2025 to 2035, suggests a robust demand for brucellosis-related products and services. Factors contributing to this growth include increased investments in vaccine development, enhanced diagnostic capabilities, and rising awareness of the disease's impact on public health. As the market evolves, stakeholders are likely to explore innovative solutions to address the challenges posed by brucellosis, thereby solidifying the industry's position in the global healthcare landscape.

## Future Outlook

The Brucellosis Market is projected to grow at a 6.93% CAGR from 2025 to 2035, driven by increased awareness, advancements in diagnostics, and rising livestock health concerns.

**New opportunities:**

- Development of rapid diagnostic kits for field use Expansion of [telemedicine services](https://www.marketresearchfuture.com/reports/telemedicine-services-market-68013) for remote consultations Investment in vaccine research for livestock and wildlife

By 2035, the Brucellosis Market is expected to achieve substantial growth and enhanced global health initiatives.

## Segment Insights

### By Application: Diagnosis (Largest) vs. Vaccination (Fastest-Growing)

The application segment of the Brucellosis Market is primarily divided into Diagnosis, Vaccination, Research, and Surveillance. Currently, the Diagnosis segment holds the largest share due to the increasing prevalence of brucellosis and the growing focus on effective detection methods. Vaccination, while smaller in comparison, is rapidly gaining traction as the importance of preventive measures becomes more recognized in combating the disease.

Diagnosis (Dominant) vs. Vaccination (Emerging)

The Diagnosis segment is characterized by innovative techniques and tests for brucellosis detection, including serological tests and molecular methods that have improved accuracy and speed. On the other hand, Vaccination represents an emerging area with a growing pipeline of vaccines aimed at preventing the disease. The increasing investment in research and development, alongside the heightened awareness of zoonotic diseases, is driving growth in the Vaccination segment, making it a pivotal focus for stakeholders in the market.

### By End Use: Veterinary (Largest) vs. Pharmaceuticals (Fastest-Growing)

The Brucellosis market is segmented into four primary end-use categories: Healthcare, Veterinary, Pharmaceuticals, and Research Institutions. Among these, the Veterinary segment holds the largest market share, driven by increased awareness and preventive measures against this zoonotic infection in livestock. The substantial investments in veterinary infrastructure globally further solidify its dominant position, reflecting its critical role in public health through livestock management. Meanwhile, the Pharmaceuticals segment, while currently smaller, is witnessing rapid growth, spurred by advancements in drug development and increasing demand for effective treatments against the disease.

Veterinary (Dominant) vs. Pharmaceuticals (Emerging)

The Veterinary end-use segment is recognized as the dominant player in the Brucellosis market, primarily due to the urgent need for effective control and prevention strategies in livestock. Its solid growth is anchored in livestock health initiatives and government regulations aimed at reducing the incidence of Brucellosis. Conversely, the Pharmaceuticals segment is emerging as a crucial area, driven by innovations in vaccine development and antibiotics that combat Brucellosis in humans and animals. This segment is gaining traction due to the increasing focus on developing targeted therapies and research-driven solutions, highlighting a shift towards personalized medicine and better management of the disease.

### By Pathogen Type: Brucella melitensis (Largest) vs. Brucella abortus (Fastest-Growing)

In the Brucellosis Market, Brucella melitensis holds the largest share due to its higher prevalence in human infections compared to other strains. This pathogen is commonly associated with unpasteurized dairy products, leading to elevated levels of awareness and resulting in preventative measures and treatment regimens. On the other hand, Brucella abortus, primarily affecting cattle, is showing significant growth trends, particularly in regions focusing on livestock disease management, thereby catering to agricultural and veterinary sectors effectively.

Brucella melitensis (Dominant) vs. Brucella suis (Emerging)

Brucella melitensis stands out as the dominant pathogen impacting the Brucellosis Market, primarily due to its association with zoonotic infections in humans. Its prevalence has driven substantial awareness and response measures globally. In contrast, Brucella suis, while being an emerging pathogen, is gaining attention due to its potential to affect wild and domestic pigs, leading to economic losses in the swine industry. As studies continue to unveil its impacts on both veterinary and public health, interest in targeted interventions and research on Brucella suis is on the rise, creating new opportunities within the market.

### By Test Type: Serological Tests (Largest) vs. Molecular Tests (Fastest-Growing)

The Brucellosis Market is distinctly characterized by its test types, with serological tests holding the largest market share due to their widespread adoption in diagnosing brucellosis. These tests are favored for their reliability and efficiency in identifying anti-brucella antibodies in patients. In contrast, molecular tests are increasingly gaining traction and represent the fastest-growing segment due to advancements in technology that allow for rapid and accurate detection of Brucella DNA, showcasing a shift in preference towards more precise diagnostic methods. Analyzing growth trends within the 'Test Type' segment reveals significant drivers contributing to the rising adoption of molecular tests. Factors such as the increasing prevalence of brucellosis globally, coupled with rising healthcare investments in diagnostic technologies, are propelling the growth of this segment. The ongoing efforts to improve diagnostic accuracy and reduce testing times are also spurring demand, making molecular tests a key focus for innovation in the market.

Serological Tests (Dominant) vs. Culture Tests (Emerging)

Serological tests remain the dominant choice in the Brucellosis Market due to their extensive use in routine diagnostics across various healthcare settings. These tests are not only cost-effective but also provide rapid results, making them suitable for large-scale screenings. On the other hand, culture tests, while currently positioned as an emerging segment, are vital for confirming brucellosis diagnosis through the isolation of the bacteria from infected tissues or fluids. Although culture tests have a longer turnaround time, their specificity complements serological testing, thus enhancing diagnostic accuracy. As treatment protocols evolve, the integration of these two testing methods is likely to optimize patient outcomes and support public health initiatives aimed at controlling brucellosis.

## Regional Market Share Analysis

### North America : Market Leader in Brucellosis

North America holds a significant position in the Brucellosis market, with a market size of $328.78M in 2025. The region's growth is driven by increasing livestock populations, heightened awareness of animal health, and stringent regulations aimed at controlling zoonotic diseases. The demand for effective vaccines and diagnostics is on the rise, supported by government initiatives to enhance animal health standards and reduce disease prevalence. The competitive landscape in North America is robust, featuring key players such as Zoetis, Merck Animal Health, and Elanco Animal Health. These companies are investing in R&D to innovate and improve treatment options. The U.S. leads the market, followed by Canada, with a strong focus on veterinary healthcare. The presence of established firms and a growing emphasis on animal welfare further solidify North America's market dominance.

### Europe : Emerging Market Dynamics

Europe's Brucellosis market is valued at $215.03M in 2025, driven by increasing livestock trade and regulatory frameworks promoting animal health. The European Union has implemented stringent regulations to control Brucellosis, enhancing the demand for effective vaccines and diagnostic tools. The focus on sustainable farming practices and animal welfare is also propelling market growth, as consumers demand higher standards in food safety and quality. Leading countries in this region include Germany, France, and the UK, where companies like Boehringer Ingelheim and Ceva Santé Animale are prominent. The competitive landscape is characterized by innovation and collaboration among key players to develop advanced veterinary solutions. The European market is witnessing a shift towards preventive healthcare, with an emphasis on vaccination programs and disease management strategies.

### Asia-Pacific : Growing Awareness and Demand

The Asia-Pacific region, with a market size of $85.15M in 2025, is witnessing a surge in demand for Brucellosis management solutions. Factors such as increasing livestock farming, rising awareness of animal health, and government initiatives to combat zoonotic diseases are driving market growth. Countries like India and China are focusing on improving veterinary healthcare standards, which is expected to boost the demand for vaccines and diagnostics in the coming years. The competitive landscape is evolving, with both local and international players entering the market. Companies like Virbac and Heska Corporation are expanding their presence in this region. The growing emphasis on food safety and quality assurance is prompting investments in veterinary health, making Asia-Pacific a promising market for Brucellosis solutions.

### Middle East and Africa : Untapped Market Potential

The Middle East and Africa region, with a market size of $28.59M in 2025, presents significant growth potential in the Brucellosis market. The increasing prevalence of livestock diseases and the need for effective management solutions are driving demand. Government initiatives aimed at improving animal health and food safety standards are also contributing to market growth. The region is gradually recognizing the importance of veterinary healthcare, leading to increased investments in disease control measures. Countries like South Africa and Kenya are at the forefront of this market, with local players and international companies exploring opportunities. The competitive landscape is characterized by a mix of established firms and emerging players, focusing on innovative solutions to address Brucellosis. The region's untapped potential makes it an attractive area for investment and development in veterinary health solutions.

## Competitive Benchmarking

The Brucellosis Market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansions. Key players such as Zoetis (US), Merck Animal Health (US), and Boehringer Ingelheim (DE) are actively pursuing strategies that enhance their market positioning. For instance, Zoetis (US) has focused on developing advanced diagnostic tools and vaccines, which are critical in managing brucellosis outbreaks. Meanwhile, Merck Animal Health (US) emphasizes a robust portfolio of vaccines and therapeutics, aiming to leverage its research capabilities to address emerging challenges in animal health. Boehringer Ingelheim (DE) appears to be concentrating on strategic acquisitions to bolster its product offerings, thereby enhancing its competitive edge in the market.The business tactics employed by these companies reflect a trend towards localizing manufacturing and optimizing supply chains to meet regional demands effectively. The market structure is moderately fragmented, with several players vying for market share, yet the collective influence of these key companies is substantial. Their strategies not only enhance their individual market positions but also contribute to a more dynamic competitive environment, where innovation and responsiveness to market needs are paramount.
In November Zoetis (US) announced the launch of a new vaccine specifically targeting brucellosis in cattle, which is expected to significantly reduce infection rates in livestock. This strategic move underscores the company's commitment to innovation and its proactive approach to addressing the challenges posed by brucellosis. The introduction of this vaccine could potentially reshape vaccination protocols and improve herd health, thereby enhancing productivity in the agricultural sector.
In October Merck Animal Health (US) expanded its distribution network in Latin America, aiming to increase access to its brucellosis vaccine. This expansion is strategically important as it allows Merck to tap into emerging markets where brucellosis remains a significant concern. By enhancing its presence in these regions, the company is likely to strengthen its market share and foster long-term relationships with local veterinarians and farmers.
In September Boehringer Ingelheim (DE) completed the acquisition of a biotechnology firm specializing in animal health diagnostics. This acquisition is indicative of the company's strategy to integrate advanced diagnostic capabilities into its existing product line, thereby providing comprehensive solutions for brucellosis management. The integration of these technologies may enhance the company's competitive positioning by offering veterinarians and farmers more effective tools for disease prevention and management.
As of December the competitive trends in the Brucellosis Market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) in diagnostics and treatment protocols. Strategic alliances among key players are shaping the landscape, fostering innovation and collaboration. The shift from price-based competition to a focus on technological advancements and supply chain reliability is evident. Companies that prioritize innovation and adaptability are likely to emerge as leaders in this evolving market.

## Report Scope

| MARKET SIZE 2024 | 657.55(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 710.65(USD Million) |
| MARKET SIZE 2035 | 1380.04(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.93% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Ceva Santé Animale (FR), Vetoquinol (FR), Heska Corporation (US), Elanco Animal Health (US), Virbac (FR) |
| Segments Covered | Application, End Use, Pathogen Type, Test Type |
| Key Market Opportunities | Advancements in diagnostic technologies enhance early detection and treatment options in the Brucellosis Market. |
| Key Market Dynamics | Rising regulatory scrutiny and advancements in diagnostics are reshaping the competitive landscape of the Brucellosis Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Brucellosis Market as of 2024?**
A: The Brucellosis Market was valued at 657.55 USD Million in 2024.

**Q: What is the projected market valuation for the Brucellosis Market in 2035?**
A: The projected valuation for the Brucellosis Market in 2035 is 1380.04 USD Million.

**Q: What is the expected CAGR for the Brucellosis Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Brucellosis Market during the forecast period 2025 - 2035 is 6.93%.

**Q: Which companies are considered key players in the Brucellosis Market?**
A: Key players in the Brucellosis Market include Zoetis, Merck Animal Health, Boehringer Ingelheim, and others.

**Q: What are the main application segments of the Brucellosis Market?**
A: The main application segments include Diagnosis, Vaccination, Research, and Surveillance.

**Q: How much was the Vaccination segment valued at in 2024?**
A: The Vaccination segment was valued at 200.0 USD Million in 2024.

**Q: What is the projected value of the Veterinary end-use segment by 2035?**
A: The Veterinary end-use segment is projected to reach 400.0 USD Million by 2035.

**Q: Which pathogen type segment had the highest valuation in 2024?**
A: The Brucella melitensis pathogen type segment had the highest valuation at 200.0 USD Million in 2024.

**Q: What are the different test types used in the Brucellosis Market?**
A: Test types include Serological Tests, Molecular Tests, Culture Tests, and Skin Tests.

**Q: What was the valuation of the Skin Tests segment in 2024?**
A: The Skin Tests segment was valued at 207.55 USD Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/brucellosis-market-5159*